CD200: Association with cancer stem cell features and response to chemoradiation in head and neck squamous cell carcinoma

Head and Neck

Volumn 37, Issue 3, 2015, Pages 327-335

  Jung, Yuh Seog ^a   Vermeer, Paola D ^b   Vermeer, Daniel W ^b   Lee, Sang Jin ^a   Goh, Ah Ra ^a   Ahn, Hyun Joo ^c   Lee, John H ^b  

^a National Cancer Center   (South Korea)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c Sungkyunkwan University   (South Korea)

Author keywords

CD200; Human papillomavirus; Immune tolerance; Neoplastic stem cells; Oropharyngeal cancer

Indexed keywords

BMI1 PROTEIN; CD200 ANTIGEN; CISPLATIN; SONIC HEDGEHOG PROTEIN; ANTIGENS, CD200; LEUKOCYTE ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; CHEMORADIOTHERAPY; CONTROLLED STUDY; EPITHELIUM CELL; EXTERNAL BEAM RADIOTHERAPY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TONSIL CANCER; TREATMENT RESPONSE; WART VIRUS; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMORADIOTHERAPY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOBLOTTING; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; TRANSFECTION; TREATMENT OUTCOME;

EID: 84923068883     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23608     Document Type: Article

References (25)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37.
2. Termine N, Panzarella V, Falaschini S, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol 2008;19:1681-1690.
3. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362-366.
4. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630-5636.
5. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-760.
6. Todaro M, Perez Alea M, Scopelliti A, Medema JP, Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008;7:309-313.
7. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol 2008;29:464-468.
8. Barclay AN, Clark MJ, McCaughan GW. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp 1986;51:149-157.
9. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001;102:173-179.
10. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000;290:1768-1771.
11. Jenmalm MC, Cherwinski H, Bowman EP, Phillips JH, Sedgwick JD. Regulation of myeloid cell function through the CD200 receptor. J Immunol 2006;176:191-199.
12. Gorczynski RM. CD200 and its receptors as targets for immunoregulation. Curr Opin Investig Drugs 2005;6:483-488.
13. Gorczynski L, Chen Z, Hu J, et al. Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells. J Immunol 1999;162:774-781.
14. Gorczynski RM, Cohen Z, Fu XM, Lei J. Anti-rat OX-2 blocks increased small intestinal transplant survival after portal vein immunization. Transplant Proc 1999;31:577-578.
15. Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 2008;366:117-122.
16. McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A 2006;103:1041-1046.
17. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007;21:566-568.
18. Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194-4197.
19. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 2007;364:778-782.
20. Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ. Cancer stem cells: how can we target them? Curr Med Chem 2008;15:3171-3184.
21. Jiang L, Li J, Song L. Bmi-1, stem cells and cancer. Acta Biochim Biophys Sin (Shanghai) 2009;41:527-534.
22. Talebian F, Liu JQ, Liu Z, et al. Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS One 2012;7:e31442.
23. Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingelhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol Head Neck Surg 2007;133:495-502.
24. Benson JD, Chen YN, Cornell-Kennon SA, et al. Validating cancer drug targets. Nature 2006;441:451-456.
25. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009;135:1137-1146.